Prostate Cancer Screening Guidelines Updated in US and Australia

In the United States, a new 2026 amendment by the American Urological Association and the Society of Urologic Oncology introduces 35 recommendations for prostate‑specific antigen (PSA) testing and biopsy. It stresses shared decision‑making, risk‑adapted screening, and recommends baseline PSA testing for standard‑risk men at ages 45‑50, with earlier testing for higher‑risk groups. The amendment also notes that prostate cancer will be the most commonly diagnosed cancer among US men in 2026, with an estimated 333,830 new cases and a 99 % five‑year survival rate for localized disease.

Australia has released its first major update to prostate‑cancer screening in a decade. The National Health and Medical Research Council‑backed guidelines, developed with the Prostate Cancer Foundation of Australia, call for biennial PSA testing for men aged 50‑69 and an initial test for men 45‑49. Men at higher risk—due to family history, BRCA2 mutations, or sub‑Saharan African ancestry—should begin testing at age 45. The guidelines also incorporate multiparametric MRI before biopsy, aiming to reduce unnecessary procedures while maintaining cancer detection. Health Minister Mark Butler and research chief Jeff Dunn described the reforms as a “watershed moment” for Australian men’s health.

A separate STAT report highlights that pre‑biopsy MRI, now standard in most wealthy nations, is used in only about one‑third of US prostate‑cancer cases, underscoring a diagnostic gap the new US amendment hopes to narrow.